Cure Lowe Foundation Selected
for Ultragenyx Rare Bootcamp
This intensive three-day program brings together leading experts in rare disease drug development, providing invaluable insights into advancing treatments from research to clinical trials. The bootcamp will cover crucial topics ranging from early research strategy and therapeutic development to clinical trial design and patient advocacy - all essential components in our mission to accelerate treatments for Lowe Syndrome.
We'll have the opportunity to learn from and connect with industry pioneers like Emil Kakkis, CEO of Ultragenyx, and engage with experts in gene therapy, regulatory affairs, and foundation building. This knowledge will be instrumental in strengthening our research strategy and expanding our impact as we work to support the development of breakthrough treatments.
Being selected for this program validates the importance of our mission and the progress we've made as a foundation. More importantly, it brings us one step closer to our goal of transforming the lives of children affected by Lowe Syndrome.
We look forward to sharing updates and insights from this experience as we continue our journey toward finding a cure for Lowe Syndrome.
Read more about the Rare Bootcamp here.
Best regards,
Sebastian Honoré
Co-founder, Cure Lowe Foundation